Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective raised by Scotiabank from $78.00 to $80.00 in a research report sent to investors on Thursday,Benzinga reports. They ...

EXCLUSIVE: The parents of two siblings with a life-limiting condition are waiting in agony to find out if health chiefs will ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with ...

Parents of children with a rare neurodegenerative disease say they are in disbelief they could within months lose access to ...

BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...